JPH0465052B

PURPOSE:An antitumor agent, containing a novel lymphotoxin and human interferon-gamma and having more remarkably improved antitumor activity than a composite pharmaceutical containing lymphotoxin derived from lymphoblastic cells and interferon-gamma. CONSTITUTION:An antitumor agent containing a novel human lymphotoxin expressed by the formula (X is Met, H, etc.; Y is saccharide chain or H) and human interferon-gamma, preferably at 20:1-1:20 compounding ratio. The lymphotoxin expressed by the formula is a new type different from an amino acid sequence of lymphotoxin derived from lymphoblastic cells, e.g. reported by Gray, etc. The antitumor activity is remarkably higher than a conventional agent and the agent is capable of exhibiting synergistic effect with the interferon-gamma. The titled antitumor agent is applicable to malignant tumors, e.g. mammary cancer, lung cancer, gastric cancer, etc.